Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
Top Cited Papers
Open Access
- 1 October 2012
- journal article
- Published by Taylor & Francis Ltd in Diabetes, Metabolic Syndrome and Obesity
- Vol. 5, 357-367
- https://doi.org/10.2147/dmso.s28340
Abstract
Peer reviewed article authored by (Rosak C, Mertes G). Read article or submit your manuscript for publishing.Keywords
This publication has 92 references indexed in Scilit:
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesThe New England Journal of Medicine, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyThe New England Journal of Medicine, 2006
- Acarbose improves fibrinolytic activity in patients with impaired glucose toleranceMetabolism, 2006
- Effects of a Single Administration of Acarbose on Postprandial Glucose Excursion and Endothelial Dysfunction in Type 2 Diabetic Patients: A Randomized Crossover StudyJournal of Clinical Endocrinology & Metabolism, 2006
- Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose toleranceEuropean Journal of Clinical Investigation, 2005
- Proinsulin Concentration Is an Independent Predictor of All-Cause and Cardiovascular MortalityDiabetes Care, 2005
- Postprandial dysmetabolism and cardiovascular disease in type 2 diabetesPostgraduate Medical Journal, 2005
- α-Glucosidase Inhibitors for Patients With Type 2 DiabetesDiabetes Care, 2005
- Reduction of Postprandial Hyperglycemia in Patients with Type 2 Diabetes Reduces NF-κB Activation in PBMCsHormone and Metabolic Research, 2004
- Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose ToleranceStroke, 2004